Therapeutic drug monitoring of anti-TNF therapy in children with inflammatory bowel disease.

Abstract

INTRODUCTION Although anti-TNF therapy has changed the scenery of pediatric inflammatory bowel diseases (IBD) immensely, there are still patients with an unfortunate outcome. Approximately one third of patients that initially respond to anti-TNF therapy will lose that response over time and need treatment optimization. Loss of response (LOR) is a big… (More)
DOI: 10.1080/14740338.2018.1413090

Cite this paper

@article{Hoeve2017TherapeuticDM, title={Therapeutic drug monitoring of anti-TNF therapy in children with inflammatory bowel disease.}, author={Karen van Hoeve and I. E. A. Hoffman and S{\'e}verine Vermeire}, journal={Expert opinion on drug safety}, year={2017}, pages={1-12} }